Ligand Pharmaceuticals | LGND - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Agenus USD 15.05M 656K 2026-03
Amgen USD 4.61B 777M 2026-06
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -170.09M 28.83M 2026-06
Baxter International USD 276M 210M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Enviri Corporation USD -35.28M 61.58M 2025-12
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -101.31M 98.97M 2026-06
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Karyopharm Therapeutics USD -26.76M 8.92M 2026-03
Ligand Pharmaceuticals USD 56.62M 3.7M 2026-06
MacroGenics USD -33.44M 21.34M 2026-03
Merck USD 840M 2.72B 2026-06
Pacira USD 9.96M 5.33M 2026-06
Pfizer USD 667M 4.32B 2026-06
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Veracyte USD 23.96M 4.88M 2026-06